US · PODD
Insulet Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Acton, MA 01720
- Website
- insulet.com
Price · as of 2025-12-31
$175.04
Market cap 17.36B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $219.31 | +25.29% |
| Intrinsic Value(DCF) | $863.73 | +393.45% |
| Graham-Dodd Method(GD) | $38.37 | -78.08% |
| Graham Formula(GF) | $132.04 | -24.57% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $19.40 | $38.46 | $965.07 | $0.00 | $0.00 |
| 2012 | $23.93 | $33.86 | $390.61 | $0.00 | $0.00 |
| 2013 | $48.50 | $57.52 | $108.86 | $0.00 | $0.00 |
| 2014 | $35.08 | $36.04 | $33.90 | $0.00 | $0.00 |
| 2015 | $31.36 | $74.07 | $0.00 | $0.00 | $0.12 |
| 2016 | $44.91 | $88.77 | $30.31 | $0.00 | $0.00 |
| 2017 | $80.33 | $57.24 | $110.11 | $0.00 | $0.00 |
| 2018 | $92.03 | $77.35 | $268.22 | $3.21 | $1.61 |
| 2019 | $179.30 | $103.31 | $184.96 | $1.55 | $7.23 |
| 2020 | $261.88 | $156.38 | $616.33 | $9.23 | $3.12 |
| 2021 | $223.26 | $161.15 | $661.72 | $8.87 | $7.10 |
| 2022 | $280.36 | $206.25 | $325.97 | $6.45 | $1.73 |
| 2023 | $179.59 | $167.59 | $580.31 | $24.55 | $108.92 |
| 2024 | $251.81 | $189.07 | $690.22 | $46.40 | $174.15 |
| 2025 | $245.45 | $219.31 | $1,110.44 | $38.37 | $132.04 |
AI valuation
Our deep-learning model estimates Insulet Corporation's (PODD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $219.31
- Current price
- $175.04
- AI upside
- +25.29%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$863.73
+393.45% upside
Graham-Dodd
$38.37
-78.08% upside
Graham Formula
$132.04
-24.57% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PODD | Insulet Corporation | $175.04 | 17.36B | +25% | +393% | -78% | -25% | 69.88 | 11.40 | 6.38 | 29.99 | — | 12.82 | 71.63% | 17.50% | 9.12% | 18.12% | 19.54% | 7.87% | 0.69 | 5.94 | 2.78 | 1.81 | 0.57 | -3979.00% | 3073.00% | 2367.00% | 2.19% | 0.84 | 21.40% | 0.00% | 0.00% | 1.12% | 37.15 | 46.60 | 6.50 | 8.10 |
| BIIB | Biogen Inc. | $191.82 | 28.15B | +13% | -50% | -35% | -56% | 21.34 | 1.51 | 2.81 | 9.91 | — | 10.66 | 70.47% | 19.14% | 13.18% | 7.39% | 8.18% | 4.50% | 0.38 | 7.63 | 2.68 | 1.70 | 1.27 | -2109.00% | 139.00% | -1848.00% | 7.43% | 0.66 | 9.68% | 0.00% | 0.00% | 1.14% | 16.36 | 14.98 | 3.13 | 3.23 |
| DGX | Quest Diagnostics Incorpo… | $211.91 | 23.57B | -3% | -58% | — | -18% | 22.31 | 3.25 | 2.11 | 13.60 | 161.86 | -6.84 | 31.93% | 14.53% | 8.99% | 15.00% | 9.14% | 6.46% | 0.96 | 6.07 | 1.04 | 0.80 | 2.96 | 1378.00% | 1178.00% | 4950.00% | 5.82% | 0.83 | 10.07% | 1.51% | 33.70% | 3.61% | 18.61 | 21.95 | 2.70 | 3.44 |
| DXCM | DexCom, Inc. | $73.43 | 28.64B | +15% | -6% | -76% | -33% | 34.42 | 10.48 | 6.18 | 24.22 | 72.96 | 10.86 | 60.10% | 19.56% | 17.94% | 34.50% | 32.99% | 13.04% | 0.51 | — | 1.88 | 1.53 | 0.41 | 4718.00% | 1560.00% | 7079.00% | 3.74% | 0.67 | 50.72% | 0.00% | 0.00% | 6.98% | 30.91 | 26.16 | 6.04 | 6.91 |
| LH | Labcorp Holdings Inc. | $289.12 | 23.97B | -28% | -60% | -89% | -45% | 27.16 | 2.77 | 1.71 | 15.16 | 148.18 | -13.50 | 26.75% | 10.87% | 6.28% | 10.53% | 8.26% | 4.77% | 0.84 | 6.77 | 1.42 | 0.99 | 3.31 | 1833.00% | 725.00% | 1005.00% | 5.06% | 0.58 | 8.29% | 1.01% | 27.40% | 2.90% | 20.12 | 25.30 | 2.19 | 3.23 |
| PHG | Koninklijke Philips N.V. | $32.00 | 30.68B | +25% | -54% | -95% | -76% | 28.63 | 2.34 | 1.44 | 11.71 | — | -29.02 | 45.18% | 7.98% | 5.02% | 7.80% | 6.50% | 3.20% | 0.74 | 4.28 | 1.32 | 0.84 | 2.00 | -22400.00% | -104.00% | -3406.00% | 3.49% | 0.15 | 5.36% | 1.28% | 36.60% | 1.28% | 21.71 | 34.62 | 1.73 | 2.09 |
| SNN | Smith & Nephew plc | $36.90 | 16.13B | +1% | -68% | — | -68% | 30.99 | 2.43 | 2.20 | 12.51 | — | 10.58 | 69.64% | 11.31% | 7.09% | 7.86% | 6.81% | 4.05% | 0.63 | 3.91 | 2.89 | 1.19 | 2.18 | -2167.00% | 470.00% | 23481.00% | 4.75% | 0.64 | 7.59% | 2.56% | 79.40% | 3.19% | 23.55 | 25.53 | 2.66 | 3.29 |
| STE | STERIS plc | $252.35 | 24.77B | -33% | -62% | -91% | -65% | 38.71 | 3.61 | 4.37 | 19.05 | 61.70 | 36.50 | 44.01% | 15.87% | 11.26% | 9.55% | 7.35% | 5.81% | 0.33 | 10.05 | 1.96 | 1.19 | 1.49 | 6273.00% | 624.00% | 2693.00% | 3.26% | 1.12 | 8.59% | 0.92% | 35.70% | 6.61% | 29.86 | 33.26 | 4.74 | 5.33 |
| WAT | Waters Corporation | $319.38 | 19.01B | -23% | -58% | -77% | -50% | 28.45 | 7.14 | 5.78 | 18.88 | 6094.04 | 27.58 | 57.77% | 28.22% | 20.30% | 29.28% | 23.09% | 13.34% | 0.55 | 17.59 | — | — | 0.81 | 47.00% | 699.00% | -1288.00% | 2.95% | — | 16.39% | 0.00% | 0.00% | 3.13% | 21.39 | 35.39 | 6.04 | 6.02 |
| WST | West Pharmaceutical Servi… | $254.34 | 18.32B | -20% | -57% | -75% | -62% | 36.79 | 5.72 | 5.91 | 24.59 | 2237.77 | 5.94 | 35.89% | 20.09% | 16.06% | 16.85% | 18.68% | 12.48% | 0.13 | 1029.00 | 3.02 | 2.09 | -0.52 | 164.00% | 626.00% | 6965.00% | 2.58% | 1.15 | 17.68% | 0.34% | 12.40% | 2.15% | 28.82 | 37.94 | 5.79 | 12.97 |
| ZBH | Zimmer Biomet Holdings, I… | $98.44 | 19.51B | +4% | -60% | -82% | -46% | 27.93 | 1.55 | 2.39 | 12.01 | — | -10.06 | 61.62% | 16.55% | 8.57% | 5.60% | 6.12% | 3.17% | 0.59 | 4.65 | 1.98 | 0.89 | 3.12 | -1986.00% | 720.00% | 2887.00% | 7.47% | 0.66 | 7.80% | 0.97% | 27.00% | 3.44% | 19.55 | 18.08 | 3.23 | 1.82 |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- CEO
- Ashley A. McEvoy
- Employees
- 3.9K
- Beta
- 1.42
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($863.73 ÷ $175.04) − 1 = +393.45% (DCF, example).